Cancer Immunology and Immunotherapy
Glenn Dranoff
apr 2011 · Current Topics in Microbiology and Immunology 344. raamat · Springer Science & Business Media
5,0star
2 arvustustreport
E-raamat
306
lehekülge
reportHinnangud ja arvustused pole kinnitatud. Lisateave
Teave selle e-raamatu kohta
The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.
Hinnangud ja arvustused
5,0
2 arvustust
Hinnake seda e-raamatut
Andke meile teada, mida te arvate.
Lugemisteave
Nutitelefonid ja tahvelarvutid
Installige rakendus Google Play raamatud Androidile ja iPadile/iPhone'ile. See sünkroonitakse automaatselt teie kontoga ja see võimaldab teil asukohast olenemata lugeda nii võrgus kui ka võrguühenduseta.
Sülearvutid ja arvutid
Google Playst ostetud audioraamatuid saab kuulata arvuti veebibrauseris.
E-lugerid ja muud seadmed
E-tindi seadmetes (nt Kobo e-lugerid) lugemiseks peate faili alla laadima ja selle oma seadmesse üle kandma. Failide toetatud e-lugeritesse teisaldamiseks järgige üksikasjalikke abikeskuse juhiseid.
